Author

Nathalie Riebel

Observed name: N. Riebel

Observed institution: PDS Biotechnology (United States)

OpenAlex ID: A5001300445

Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).

2023 · Katharine Andress Rowe Price, John M. Kaczmar, et al. · Journal of Clinical Oncology · 11

PDS0101, a novel type I interferon and CD8 T-cell activating immunotherapy, in combination with pembrolizumab in subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC).

2022 · Jared Weiss, Ashish V. Chintakuntlawar, et al. · Journal of Clinical Oncology · 5

924P Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)

2023 · K.J. Harrington, J. Weiss, et al. · Annals of Oncology · 2

A Vaccine (PDS0101) Alone or in Combination with Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

2024 · D.M. Routman, K. Van Abel, et al. · International Journal of Radiation Oncology*Biology*Physics · 1

44P HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy

2023 · L.V. Wood, S. McCarthy, et al. · ESMO Open · 1

Works count: 5

Citation count: 20

H-index: 2

I10-index: 1